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 SYNOPSIS 
Name of sponsor company : Leading Edge Marketing 
Name of finished product : VigRX Plus capsules 
Name of active ingredients:  
Panax ginseng (Korean Red Ginseng)  
Serenoa repens (Saw Palmetto) 
Crataegus rivularis ( Hawthorne) 
Ginkgo biloba 
Turnera diffusa (Damiana) 
Tribulus terrestris 
Erythroxylum catuaba  
Ptychopetalum olacoides (Muira Puama)  
Cuscuta chinensis 
Epimedium sagittatum  
Bioperine (extract from Piper nigrum fruit ) 
 
Title of the study: A triple blind, placebo controlled, randomized study to evaluate the 
safety and efficacy of VigRX Plus capsules as a dietary supplement to improve erectile 
function and maintain Male Sexual Health. 
Investigators and study centres:  
1)Dr. Gaurang Shah 
Jivdaya Hospital,Dharmoday bldg, Jivdaya lane, L.B.S. Marg, Ghatkopar (W), Mumbai-
86.INDIA.Mob: 9821019432.  
 
2)Dr. R. K. Shimpi 
Dept. of Urology,Noble Hospital, 153,Magarpatta City Road, Hadapsar,Pune-411 013. 
INDIA.Mob : 9822059799 
 
3)Dr. Suresh Patankar 
Institute of urology,Survey no. 32/2A, Erandwane, Behind  Mehendale  garage,Gulwani 
Maharaj road, Pune-4.INDIA.Mob : 9881256992  
 
4)Dr. Manoj Chaudhari 
169, Parvati gaon, Bhaghirathi Medical Foundation, Pune – 400009, Phone. 9225571450 
 
5)Dr. Vilas Sabale 
First floor, Vithal Acrade, Near Rupee bank, Pune Nasik Highway,Bhosari, Pune-411039 
Mobile: 9822004630 
Study period: 
Date of first enrollment: 07/05/2009 
Date of last completed: 17/12/2009 
Phase of study : Therapeutic exploratory CSR, VigRX Plus  Version 1.2  08/05/2010 
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Objectives 
Primary objective 
To evaluate the efficacy of VigRX Plus capsules as a dietary supplement to improve 
erectile function as assessed by Erectile function subscale of IIEF Questionnaire (IIEF-A) 
from baseline to end of treatment as compared to placebo. 
Secondary objectives 
•  To evaluate the efficacy of VigRX Plus capsules as a dietary supplement for Male 
Sexual Health as assessed by IIEF (Total)   (International Index of Erectile Function) 
questionnaire from baseline to end of treatment as compared to placebo 
•  To evaluate the efficacy of VigRX Plus capsules as a dietary supplement for Male 
Sexual Health as assessed by IIEF-B questionnaire (sum of all the subscales of IIEF 
except erectile function subscale) from baseline to end of treatment as compared to 
placebo 
•  To  evaluate  the  impact  of  VigRX  Plus  capsules  as  a  dietary  supplement  for  Male 
Sexual  Health  as  assessed  by  EDITS questionnaire  (Patient  &  Partner  version)  as 
compared to placebo 
•  To  evaluate  the  safety  of  VigRX  Plus  capsules  as  a  dietary  supplement  for  Male 
Sexual Health from baseline to end of treatment as compared to placebo 
•  To assess the effect of VigRX Plus on the sperm count, motility, semen volume from 
baseline to end of treatment. 
•  To assess the effect of VigRX Plus on Serum testosterone from baseline to end of 
treatment as compared to placebo 
Diagnosis and main criteria for inclusion 
1.  Male subjects aged between 25-50 years 
2.  Subject having a monogamous, heterosexual relationship 
3.  Male subjects with IIEF-A score 11 to 23 & IIEF-B score 21 to 35 at screening visit & 
baseline visit 
4.  Subject provides written informed consent and comes for regular follow up CSR, VigRX Plus  Version 1.2  08/05/2010 
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Methodology  
75  males  between  25-50  years  of  age  were  recruited  to  get  60  completed  cases. 
Subjects with an IIEF erectile function domain score of 11-23 and remaining domains 
score of 21-35 were eligible for the study. For each subject the study terminated after a 
maximal  period  of  84  days  from  enrollment  and  included  5  follow  up  visits.  After 
consenting to participate subjects were put on 15 days wash-out period before being 
administered the investigational product or placebo. On baseline visit (Day 1), medical 
history  and  physical  examination  were  performed,  IIEF  Total  questionnaire  was 
assessed  and the trial medications  were  dispensed.  At  all  the follow-up  visits  (at  an 
interval of 28 days) each subject was administered a new IIEF (Total) and an EDITS 
questionnaire. Each subject received another supply of the trial medications during these 
visits. On Day 28 and Day 84 EDITS questionnaire partner version scores were obtained 
from partners who consented for the same. Additionally at these visits subjects rated the 
tolerability of the treatment they received. At the end of treatment investigator’s global 
assessment of therapy and subject’s opinion on continuing with the trial medication was 
obtained. 
 
Number of patients planned: 60 completed cases 
Number of patients analysed :75 
Test product, dose and mode of administration, batch number 
VigRX Plus -2 capsules (each containing 360 mg of active composition) twice a day with 
meals for 12 weeks, Batch No: VP01. 
Reference therapy: Placebo 2 capsules twice a day with meals for 12 weeks  
Batch No: VX01, 
Criteria for evaluation:  
Primary efficacy evaluation 
Improvement in IIEF-A (Erectile function domain of the International Index of Erectile 
Function) score for erectile function domain as compared to placebo 
Secondary efficacy evaluation:  
•  Increase  in  total  score  of  quality  of  sexual  life  questionnaire-IIEF  (Total)  as 
compared to placebo  CSR, VigRX Plus  Version 1.2  08/05/2010 
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Secondary efficacy evaluation (continued)  
•  Improvement  in  IIEF-B  (other  than  the  erectile  function  domain)  score  as 
compared to placebo  
•  Satisfaction with treatment (EDITS Patient & partner version) as compared to 
placebo 
•  Improvement in Semen Analysis Parameters as compared to placebo 
•  Improvement in Serum Testosterone (Total) levels , as compared to placebo 
Safety  
Monitoring of adverse events. Clinical examination, Assessment of vitals and laboratory 
parameters.  
Statistical methods 
Analysis for safety was done on an intention-to treat population. This included subjects 
who received at least one dose of treatment post randomization and for whom at least 
one post baseline measurement was available. Missing data were imputed using last 
observation carried forward (LOCF) method.  
Analysis of efficacy was primarily done on a per protocol data set constituting of subjects 
completing all the protocol required visits. Changes from baseline in IIEF scores were 
assessed using analysis of covariance (ANCOVA). Data on EDITS (patient and partner 
versions) were analysed by independent sample t test. Chi-square test was used to 
analyse investigators’ assessment and subjects opinion across the two groups. All 
statistical tests were applied at 5% level of significance.    
Results 
Efficacy 
Treatment with VigRX Plus resulted in a statistically significant increase (p<0.0001) of 
IIEF-A, IIEF-B and IIEF-Total scores as compared to placebo, on Day 84 (end of 
treatment).In subjects treated with VigRX Plus, mean increases from baseline to end of 
treatment for IIEF-A, IIEF-B and IIEF-Total were 9, 20.1 and 11.56 respectively. The 
corresponding increases in the placebo group were 0.62, 1 and 0.68.Treatment 
satisfaction as assessed by EDITS (patient version) was statistically significantly higher 
in the VigRX Plus group as compared to placebo on Day 28, Day 56 and Day 84. At the 
end of treatment, mean EDITS score was 82.31 in the VigRX Plus group and 36.78 in 
the placebo group.  CSR, VigRX Plus  Version 1.2  08/05/2010 
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Results (continued) 
Female partners reciprocated the satisfaction levels experienced by their male 
counterparts treated with VigRX Plus, with the mean EDITS (partner version) score of 
69.58 in the VigRX Plus group being statistically greater than that of 25.5 in the placebo 
group.  
There was no statistically significant difference in the sperm count, semen volume and 
sperm motility between the two treatment groups. Serum Testosterone levels did not 
change significantly in any of the study groups. 
At the end of study, global assessment of therapy by investigator clearly saw a 
superiority of outcomes in subjects receiving VigRX Plus as compared to those receiving 
placebo, with statistical significance. Subjects’ opinion was also statistically significant in 
favour of VigRX Plus. 
Safety 
VigRX Plus and placebo both were safe and well tolerated in the study. Changes in 
laboratory and vital signs were clinically insignificant. The only serious adverse event 
reported in this study was when one subject from the VigRX Plus group suffered from 
infection due to malarial parasite and was subsequently withdrawn from the study. 
Conclusion 
In conclusion, use of VigRX Plus for twelve weeks was significantly better than placebo 
in improving erectile function in subjects with sexual dysfunction. It was also significantly 
superior to placebo in improving the other aspects of sexual health such as libido, 
intercourse satisfaction, orgasmic function and overall satisfaction. The enhancement of 
sexual function was endorsed by female partners of subjects receiving VigRX Plus. 
VigRX Plus was safe and well tolerated in subjects with male sexual dysfunction. CSR, VigRX Plus  Version 1.2  08/05/2010 
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1  ETHICS 
The  study  was  conducted  in  accordance  with  International  Conference  of 
Harmonization’s  (ICH)-Good  Clinical  Practices  (GCP)  and  the  applicable  regulatory 
requirements of India. Prior to study initiation, the study protocol and amendments were 
submitted  to  an  appropriately  constituted  Independent/  Institutional  Ethics  Committee 
(IEC),  in  agreement  with  local  legal  prescriptions,  for  formal  approval  of  the  study 
conduct.  The  study  commenced  only  after  an  affirmative  decision  of  the  EC/IRB 
concerning the conduct of the study was made in writing to the investigator and a copy 
provided  to  the  sponsor.  Freely  given  informed  consent  was  obtained  from  study 
participants and their female partners prior to their entry into the trial. 
 
Study Site  Ethics Committee 
Dr. Gaurang Shah 
Jivdaya Hospital, 
Dharmoday bldg,  
Jivdaya lane, L.B.S. Marg,  
Ghatkopar(W), Mumbai-86. 
Mob: 9821019432.  
Independent Ethics Committee 
4, Sharavati, Worli Sea Face, Worli, Mumbai 
400030. 
Tel : 91-22-65748188 
Fax : 91-22-24966602 
Dr. Suresh Patankar 
Institute of urology,  
Survey no. 32/2A, Erandwane,  
Behind Mehendale garage, 
Gulwani Maharaj road, Pune-4. 
Mob : 9881256992  
Ethical Committee, AMAI Charitable Trust 
C/O Institute of Urology 
S.No. 32/2A, Erandwane,  
Behind Mehendale Garage,  
Gulwani Maharaj Street, 
Pune 411004. 
Dr. R. K. Shimpi 
Dept. of Urology, 
Noble Hospital, 153,Magarpatta 
City Road, 
Hadapsar, 
Pune 411 013. 
Mob : 9822059799 
Ethical Committee, 
Noble hospital, 
153,Magarpatta City Road, 
Pune - 411013. 
Tel: (020)66285000 / 66295000 
Fax: (020)66285199 
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2  INTRODUCTION 
It has been reported from various studies in the general population and primary care that 
around 15-20% of men describe some sort of sexual problem 
1. Erectile dysfunction is 
one of the most common forms of sexual disorder and according to a survey, the 
Massachusetts Male Aging Study, 52% of men beyond 40 years of age may have some 
degree of erectile failure
2. 
 
Current pharmacologic treatment of male sexual dysfunction includes a number of 
interventions; including oral phosphodiesterase type 5 (PDE5) inhibitors and 
intracorporeal agents with vasodilatory effects
3. PDE5 inhibitors (e.g Sildenafil) for 
erectile dysfunction have revolutionised the treatment of male sexual dysfunction and 
are among the best selling drugs worldwide
4. While normal sexual function involves 
successful integration of biological, psychological, and interpersonal influences
3, 
Sildenafil is known only to facilitate erections and not restore sexual desire (does not 
work without sexual stimulation), overcome sexual resistance or treat relational discord 
4.
   
The use of Sildenafil necessitates caution in cardiac failure and when used within six 
months of acute myocardial infarction and stroke. It is inadvisable in patients with 
unstable angina pectoris. The co-administration of Sildenafil with organic nitrates, for 
example, glyceryl trinitrate or isosorbide dinitrate, is unsafe. The relative 
contraindications to Sildenafil in cardiovascular disease are uncontrolled hypertension 
and impaired cardiac reserve. The most common side effects are headache, flushing 
(due to vasodilation), and dyspepsia (due to relaxation of the smooth muscle of the 
gastroesophageal sphincter with reflux 
5. Further, several cases of non-arteritic anterior 
ischaemic optic neuropathy (NAION) have been reported since 2005 in users of PDE5 
inhibitor agents. Following a series of such case reports, WHO and FDA have labeled 
the association between use of PDE5 inhibitors and risk of NAION as “possibly” causal 
6.  
While concerns of safety and limited efficacy still remain as longstanding treatment gaps 
in current therapy for male sexual dysfunction, several herbal therapies have provided 
suggestive  evidence  of  efficacy  in  controlled  clinical  trials.  The  present  study  was 
therefore undertaken to evaluate the safety and efficacy of an herbal formulation VigRX 
Plus  containing  Korean  red  ginseng  a  widely  used  herbal  ingredient  and  others  in CSR, VigRX Plus  Version 1.2  08/05/2010 
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subjects with male sexual dysfunction. The study was based on the initial aphrodisiac 
activity exhibited by VigRX Plus in significantly reducing the ejaculation latency and post 
ejaculatory interval in male albino rats when compared to vehicle control. Treatment with 
VigRX Plus had resulted in a significant increase in ejaculation frequency on day 7 and a 
non significant increase on day 14 with marginal increase in testosterone concentration 
in  serum  and  number  of  spermatogonia  cells  in  seminiferous  tubules  of  testes. 
(Unpublished report). 
 A set of preclinical studies
7 (at two different doses and duration) of an earlier marketed 
herbal combination VigRX, (devoid of 3 additional ingredients-Tribulus, Damiana, and 
Bioperine that are present in VigRX Plus) in a Sprague-Dawley rat model demonstrated 
a marked enhancing effect on the sexual activity of rats. In vitro assays determined that 
VigRX is able to inhibit the enzyme Rho-kinase. Also, VigRX was shown to be free from 
pharmaceutical adulterants, including phosphodiesterase type 5 (PDE -5) inhibitors and 
related analogues. 
With the accrued preclinical evidence it was imperative to investigate the role of VigRx 
Plus in humans. Hence, in the present study, efficacy and safety of VigRX Plus was 
explored in human male subjects with sexual dysfunction.  
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3   STUDY OBJECTIVES 
Primary objectives 
To evaluate the efficacy of VigRX Plus capsules as a dietary supplement to improve 
erectile function as assessed by Erectile function subscale of IIEF Questionnaire (IIEF-
A) from baseline to end of treatment as compared to placebo. Index) questionnaire as 
compared to placebo 
Secondary objectives 
•  To evaluate the efficacy of VigRX Plus capsules as a dietary supplement for Male 
Sexual Health as assessed by IIEF (Total)   (International Index of Erectile Function) 
questionnaire from baseline to end of treatment as compared to placebo 
•  To evaluate the efficacy of VigRX Plus capsules as a dietary supplement for Male 
Sexual Health as assessed by IIEF-B questionnaire (sum of all the subscales of IIEF 
except erectile function subscale) from baseline to end of treatment as compared to 
placebo 
•  To  evaluate  the  impact  of  VigRX  Plus  capsules  as  a  dietary  supplement  for  Male 
Sexual Health as assessed by EDITS questionnaire (Patient & Partner version) as 
compared to placebo 
•  To  evaluate  the  safety  of  VigRX  Plus  capsules  as  a  dietary  supplement  for  Male 
Sexual Health from baseline to end of treatment as compared to placebo 
•  To assess the effect of VigRX Plus on the sperm count, motility, semen volume from 
baseline to end of treatment. 
•  To assess the effect of VigRX Plus on Serum testosterone from baseline to end of 
treatment as compared to placebo. CSR, VigRX Plus  Version 1.2  08/05/2010 
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4  INVESTIGATIONAL PLAN 
4.1  OVERALL STUDY DESIGN AND CHOICE OF CONTROL GROUP 
This was a multicentre, triple blind, randomized, parallel group study of VigRX in 
subjects with male sexual dysfunction. The control used for this study was placebo.  
4.2  METHODOLOGY 
This was a twelve week study wherein subjects after a wash out period of 7/15 days, 
were randomized to receive either VigRX Plus or placebo capsules (Fig1) After their 
entry into the trial, eligible subjects were administered IIEF questionnaires for baseline 
assessment of sexual dysfunction. Safety assessment through medical history, vitals 
and systemic examination, monitoring of adverse events were performed at baseline and 
each follow up visit. Follow up visits were scheduled on Day 28, Day 56, Day 84 of 
study. At each of these visits, in addition to the IIEF evaluation subjects administered an 
EDITS (patient version) questionnaire to assess treatment satisfaction. EDITS (partner 
version) data on female partners of trial subjects was acquired on day 28 and day 84. 
Efficacy evaluation by semen analysis parameters (semen volume, sperm count, and 
semen motility) and serum testosterone was done at screening visit and at end of 
treatment. 
Laboratory evaluation and ECG were scheduled at start and end of treatment. Global 
assessment of therapy by investigator, subjects’ opinion and assessment of tolerability 
were performed at treatment end (Day 84). 
 
  CSR, VigRX Plus  Version 1.2  08/05/2010 
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A detailed schedule of study visits and procedures are displayed in Table 1 
Table 1. Visit specific schedule 
Parameters 
Screening 
(Day -7/-15) 
Baseline 
(Day 1) 
Day 28  Day 56  Day 84 
Subject Informed 
Consent 
X  -  -  -  - 
Subject’s Female 
Partner Informed 
Consent 
-  -  X  -  - 
Vitals  X  X  X  X  X 
Systemic 
Examination 
X  X  X  X  X 
TSH  X  -  -  -  - 
S. Prolactin  X  -  -  -  - 
S. Testosterone  X  -  -  -  X 
CBC & ESR  X  -  -  -  X 
ECG  X  -  -  -  X 
Serum Creatinine  X  -  -  -  X 
Urine Routine  X  -  -  -  X 
RBS  X  -  -  -  - 
SGPT  X  -  -  -  X 
Semen Analysis  X  -  -  -  X 
 
IIEF T Questionnaire  X  X  X  X  X 
EDITS Questionnaire 
(patient version) 
-  -  X  X  X 
EDITS Questionnaire 
(partner version) 
-  -  X  -  X 
Subject Diary  -  X  X  X  X 
Dispensing of Study 
Medication 
-  X  X  X  - 
Monitoring of 
Adverse / Serious 
Adverse Events 
-  X  X  X  X 
IP compliance 
- 
-  X  X  X 
Global assessment by 
the investigator 
- 
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Fig 1 : Study design  
 
 
 
 
 
 
 
 
 
 
 
 
 
4.3  SELECTION OF STUDY POPULATION 
4.3.1  INCLUSION CRITERIA 
Patients satisfying all of the following inclusion criteria were to be included in the study  
1.  Male aged between 25-50 years 
2.  Subject having a monogamous, heterosexual relationship 
3.  Male subjects with IIEF-A score 11 to 23 & IIEF-B score 21 to 35 at screening visit & 
baseline visit 
4.  Subject provides written informed consent and comes for regular follow up 
4.3.2  EXCLUSION CRITERIA 
Patients meeting any of the following exclusion criteria were to be excluded from the 
study 
1.  Subjects with major  psychiatric disorders  
2.  Has  a  history  of  stroke,  myocardial  infarction,  coronary  artery  disease,  cardiac 
failure, angina, life-threatening arrhythmia within the past 6 months.  
3.  Has a history of diabetes 
4.  Has a history of spinal cord injury or a radical prostatectomy or radical pelvic surgery.  
5.  Has  anatomical  deformity  of  the  penis  which  has  a  severe  effect  on  sexual 
functioning 
6.  Is a k/c/o HIV / AIDS 
7.  Is know to suffer from sexually transmitted diseases(STDs) at screening visit  
 
Screening  R 
Active 
Placebo 
Day 1  Day 28  Day 56  Day (-7 / -15)  Day 84 CSR, VigRX Plus  Version 1.2  08/05/2010 
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8.  Chronic  Alcoholics  showing  withdrawal  symptoms  or  subjects  having  medication 
(opiates etc) or drug (marijuana, cocaine etc)/ Nicotine/Caffeine dependence 
9.  Is  using  medications  that  are  known  to  cause  sexual  dysfunction  (cimetidine, 
spironolactone, thiazides, β-adrenergic blockers, anti- depressants etc.) 
10. Has a major illness that in the opinion of the investigator would interfere with the 
conduct of the study.  
11. Has participated in a clinical drug study within the last 30 days prior to entering this 
study.  
12. Subject with Liver dysfunction as evidenced by SGPT level of 1.5 X ULN. 
13. Subject  with  Renal  dysfunction  as  evidenced  by  Serum  Creatinine  level  of  1.5 X 
ULN.  
14. Has an abnormal thyroid stimulating hormone (TSH) level lower than 30% of LLN or 
more than 30% of ULN.  
15. Has  erectile  dysfunction  caused  by  neurological  or  endocrine  factors  such  as 
hyperprolactinemia or low serum testosterone levels (<200 ng/dl).   
16. Subjects already  taking any medications for the study indication & do not wish to 
discontinue the same 
17. Subject not ready to sign the consent & unable to comply with the protocol 
18. Subjects whose female partners are Pregnant  
   
4.3.3  WITHDRAWAL CRITERIA 
Subjects meeting any of the following criteria were to be withdrawn from the study 
•  Earnest request of the subject assigning a reason for the same. 
•  Discretion of the Investigator. 
•  Repeated protocol criteria deviations. 
•  Serious adverse events where continuation of study possess serious risk to the 
subject. 
•  Subject  has  consumed  less  than  80%  of  the  total  dose  that  needs  to  be 
consumed in the period between follow-ups and in the opinion of the investigator 
needs to be withdrawn from the study  
•  Subject  consumes  any  other  medicines  used  for  the  treatment  of  Sexual 
Dysfunction.  CSR, VigRX Plus  Version 1.2  08/05/2010 
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•  Subject consumes any medications that are mentioned in the list of prohibited 
medications. 
4.3.4  DROP OUT / LOST TO FOLLOW UP CRITERIA 
Subject was to be considered as a dropout if he does not report for the follow up within –
5 or + 5 days of his scheduled visit day but does report to investigator later and in the 
opinion of the investigator needs to be consider as drop out.  
Subject was to be considered as a lost to follow up if he does not report to investigator at 
all after a particular follow up visit during therapy period. 
 
4.4  TREATMENTS ADMINISTERED 
4.4.1  IDENTITY OF INVESTIGATIONAL PRODUCT 
Each capsule of VigRX Plus contains the following 
 
Table 2.Composition of  VigRX Plus 
Ingredients 
(Latin Names) 
Part used 
 
Actual wt / caps 
(mg) 
Panax ginseng (Korean Red Ginseng)   Root  100.000 
Serenoa repens (Saw Palmetto)  Berry  100.000 
Crataegus rivularis ( Hawthorne)            Berry  100.000 
Ginkgo biloba  Leaf  100.000 
Turnera diffusa (Damiana)  Leaf  100.000 
Tribulus terrestris  Vine  075.000 
Erythroxylum catuaba   Bark  050.000 
Ptychopetalum olacoides (Muira Puama)   Bark  050.000 
Cuscuta chinensis  Seed  025.000 
Epimedium sagittatum   Leaf  015.000 
Bioperine (extract from Piper nigrum fruit )                -  005.000 
Total amount  720.000 
   
Additional ingredients: dicalcium phosphate, cellulose, croscarmellose sodium, stearic 
acid, silicon dioxide, magnesium stearate, FD&C Red #40 
Presentation: White plastic bottles each containing 128 capsules 
Placebo capsules were similar to IP in appearance and were made up of CMC 
(Carboxymethyl cellulose) CSR, VigRX Plus  Version 1.2  08/05/2010 
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4.4.2  DOSES AND ADMINISTRATION 
VigRX Plus and placebo were to be taken orally with meals at a dose of 2 capsules twice 
daily for 12 weeks. Each capsule contained 360 mg of the active composition mentioned 
above. The IP and placebo were administered to subjects in the following regimen. 
Table 3. Treatment regimen  
*Each capsule contained 360 mg of the active composition of VigRx Plus 
4.4.3  BLINDING AND RANDOMISATION 
A  total  of  72  subjects  were  expected  to  be  recruited  from  the  investigator’s  clinical 
practices or referring physicians. Each subject satisfying the inclusion/exclusion criteria 
was  to  be  recruited  in  the  study  and  be  assigned  to  one  of  the  treatment  groups 
according to a randomization schedule. A research coordinator, who was not directly 
involved  in  trial-related  activities,  performed  the  randomization  and  blinding  to  avoid 
bias.  
4.4.4  PRIOR AND CONCOMITANT THERAPY 
During the course of the study, the subjects were prohibited from consuming any other 
medication  used  in  the  treatment  of  Male  Sexual  Dysfunction.  A  list  of  medications 
prohibited in the study is provided in Appendix 10.1.1. No other herbal medication other 
than that dispensed during the study was allowed. Subjects who were required to take 
medicines  for  any  other  complaints  were  to  do  so  only  in  consultation  with  the 
Investigator. Use of any concomitant medication was to be recorded in the case report 
form (CRF). Subjects were not advised any specific lifestyle & dietary changes upon 
enrolment in the study & throughout the duration of the study. 
4.4.5  TREATMENT COMPLIANCE 
In  order  to  ensure  treatment  compliance,  adequate  instructions  were  to  be  given  to 
subjects regarding trial procedures during the informed consent process. Subjects were 
provided with a memory card for follow up visits and test requisition forms for laboratory 
investigations. At each visit, a record of dispensed and returned medication was to be 
maintained to determine subject’s compliance to treatment. 
Group  Morning  Night  Route of 
Administration 
Treatment 
Duration 
VigRX 
Plus 
2Capsules* of    
VigRX Plus 
2 Capsules* of  
VigRX Plus 
Placebo  2 Capsules of 
Placebo 
2 Capsules of 
Placebo 
ORAL 
(Capsules to be 
taken with  meals) 
12 weeks 
(from day 1  
to  
day 84) CSR, VigRX Plus  Version 1.2  08/05/2010 
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4.5  EFFICACY AND SAFETY VARIABLES 
4.5.1  PRIMARY EFFICACY VARIABLES 
4.5.1.1  INTERNATIONAL INDEX OF ERECTILE FUNCTION -ERECTILE FUNCTION 
DOMAIN (IIEF-A) 
 
It is an internationally accepted instrument described by Rosen et al 
8 for measuring 
erectile dysfunction and monitoring response to treatment. 
The erectile function domain (items1-6 of the index) designated as IIEF A in this study 
was used to measure erectile dysfunction. It provided information on the subject’s ability 
to achieve and maintain an erection. The erectile function domain consists of six 
questions concerning erection frequency (question [Q]1), erection firmness (Q2), 
frequency of partner penetration (Q3), frequency of maintaining erection after 
penetration (Q4), ability to maintain erection to completion of intercourse (Q5), and 
confidence in achieving and maintaining erection (Q6), all during the previous 4 weeks. 
The primary efficacy variable consisted of the change in mean erectile function domain 
score (IIEF A) from baseline to end point.  
 
4.5.2  SECONDARY EFFICACY VARIABLES 
4.5.2.1  INTERNATIONAL INDEX OF ERECTILE FUNCTION- TOTAL (IIEF-TOTAL)  
 
The IIEF addresses the relevant domains of male sexual function (erectile function, 
orgasmic function, sexual desire, intercourse satisfaction, and overall satisfaction), is 
psychometrically sound, and has been linguistically validated in 10 languages. This 
questionnaire is readily self-administered in research or clinical settings. The IIEF 
demonstrates the sensitivity and specificity for detecting treatment-related changes in 
patients with erectile dysfunction
8.  
 
Each item on the IIEF questionnaire is scored on 5 point Likert scale. Scores for each 
domain are variable and total score range is 5 to 75. Maximum possible score for 
erectile function is 30. The complete IIEF questionnaire is provided as Appendix 10.1.3 
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4.5.2.2  INTERNATIONAL INDEX OF ERECTILE DYSFUNCTION (OTHER THAN THE 
ERECTILE FUNCTION DOMAIN)-(IIEF B) 
The section of the international index other than the erectile function domain, designated 
as IIEF B in this study, was used to measure other aspects of sexual dysfunction 
besides erectile dysfunction. It gives information on, orgasmic function, sexual desire, 
intercourse satisfaction and overall sexual satisfaction in a subject.  
 
4.5.2.3  ERECTILE DYSFUNCTION INVENTORY OF TREATMENT SATISFACTION (EDITS- 
Patient and Partner version) 
 
Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) was developed by 
Althof, Corty et al 
9 to examine the degree of satisfaction with different treatment 
modalities for ED. Separate questionnaires are available for both the subject and the 
subject’s partner. With the partner version EDITS allows partner satisfaction an 
important determinant—especially for sexual dysfunction but seldom evaluated to be 
measured and investigated. 
 
4.5.2.4  SEMEN ANALYSIS 
Semen analysis is a measure to determine the semen quality in terms of the ability of 
sperm to accomplish fertilization. A semen analysis does not diagnose fertility or 
infertility but provides a relative measure of semen quality compared to the general 
population of men. Since it is the sperm that is of importance to male fertility, semen 
quality involves both sperm quantity and quality.  
Most available studies on oral phosphodiesterase inhibitors demonstrate a significant 
increase in sperm motility and viability both in vivo and in vitro, which seems to be 
enhanced at low doses and reduced at high concentrations 
10. In the current study 
semen analysis of subjects was conducted at screening and end of treatment to 
investigate whether administration of the VigRX Plus has any modifying effect on 
seminal parameters   
The following parameters were measured in semen analysis:  
o  Volume and consistency of semen 
o  Sperm count: Sperm count measures the concentration of sperm in a man's 
ejaculate. Anything over 20 million sperm per milliliter is considered normal.  CSR, VigRX Plus  Version 1.2  08/05/2010 
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o  Sperm motility describes the ability of sperm to move properly towards an ovum. 
A more specified measure is motility grade, where the motility of sperm are 
divided into four different grades: 
Grade IV:  Sperm with progressive motility. These are the strongest and swim fast in a 
straight line. 
Grade III: (non-linear motility): These also move forward but tend to travel in a curved or 
crooked motion.  
Grade II: These have non-progressive motility because they do not move forward 
despite the fact that they move their tails 
Grade I: These are immotile and fail to move at all 
The percentage of each motility grade was recorded after 1h, 2h, 3h and 6h of collection. 
4.5.2.5  SERUM TESTOSTERONE  
While the role of testosterone in mediating penile erection may be largely unknown, 
routine testing of serum testosterone has been recommended for initial evaluation of ED. 
In this study serum testosterone levels were evaluated for changes from baseline to 
endpoint (Day 84) across the two study groups. 
4.5.2.6  GLOBAL ASSESSMENT OF THERAPY BY INVESTIGATOR 
 
Global assessment of therapy was made by the investigator, based on the criteria 
described below: 
 
Table 4. Criteria for global assessment by investigator 
 
Excellent  Improvement  in  all  the  IIEF-A,  IIEF-B,  EDITS  (patient  &  partner 
versions) Questionnaires , Semen Analysis & Serum testosterone 
Very Good  Improvement in IIEF-A, IIEF-B, EDITS (patient version) Questionnaires 
& Semen Analysis 
Good  Improvement in IIEF-A, IIEF-B, EDITS (patient version) Questionnaires 
 
Fair   Improvement in IIEF-A & IIEF-B Questionnaires 
 
Poor  No Improvement 
4.5.2.7  SUBJECT’S OPINION 
At the end of the study period, subjects were asked if they preferred to continue using of 
the study product in future, for their sexual dysfunction CSR, VigRX Plus  Version 1.2  08/05/2010 
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4.5.3  APPROPRIATENESS OF MEASUREMENTS 
 
The International Index of Erectile Function (IIEF) is a widely used, multi-dimensional 
self-report instrument for the evaluation of male sexual function. It is has been 
recommended as a primary endpoint for clinical trials of erectile dysfunction (ED) and for 
diagnostic evaluation of ED severity. The IIEF was developed in conjunction with the 
clinical trial program for Sildenafil, and has since been adopted as the 'gold standard' 
measure for efficacy assessment in clinical trials of ED and its use in classifying ED 
severity and prevalence. The IIEF meets psychometric criteria for test reliability and 
validity, has a high degree of sensitivity and specificity, and correlates well with other 
measures of treatment outcome. It has demonstrated consistent and robust treatment 
responsiveness in studies in USA, Europe and Asia, as well as in a wide range of 
etiological subgroups
11.   
 
Limitations
11- The IIEF focuses only on current sexual functioning and provides 
superficial assessment of domains of sexual functioning other than erection. It does not 
provide any specific information about the partner relationship or sexual functioning of 
the partner. It could be argued that these are important areas for assessment in clinical 
practice. It was thus important to include EDITS questionnaire to assess treatment 
satisfaction of the partner.  
 
4.5.4  SAFETY AND TOLERABILITY VARIABLES 
Safety was assessed primarily through incidence of adverse events (AE), clinical and 
laboratory evaluation of the subject.  
4.5.4.1  ADVERSE EVENTS 
An adverse event is defined as any untoward medical occurrence in a subject who has 
been administered an investigational product and does not necessarily have a causal 
relationship. An adverse event can therefore be any unfavourable and unintended sign 
(including an abnormal laboratory finding), symptom or disease temporarily associated 
with the use of the IP whether or not related to the IP. 
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Adverse events were further classified into serious and non-serious. Definition of serious 
adverse events (SAE) is described in Appendix 10.1.2 of this report. All adverse events 
whether serious or non serious, whether observed or reported by the patient were to be 
evaluated by the investigator and recorded in the AE section of the subject’s case report 
form. Adverse event reporting required the severity of the event, treatment administered, 
any change in study drug, investigator attribution to study drug and outcome status to be 
documented in the CRF. 
 
4.5.4.2  CLINICAL AND LABORATORY EVALUATION 
 
Physical examinations and monitoring of vital signs (systolic and diastolic blood 
pressure, respiration rate and pulse rate) were to be conducted at screening, baseline 
and at each follow up visit. Laboratory evaluations consisting of haematological, clinical 
chemistry and urinalysis parameters were required at the screening visit and at the end 
of treatment phase on Day 84. In addition, a 12-lead Electrocardiogram (ECG) was to be 
performed at these visits. Any clinically significant abnormality in any of the above 
mentioned safety parameters was to be recorded as an adverse event in the respective 
pages of the CRF. 
4.5.4.3  TOLERABILITY 
In addition to the above mentioned safety parameters, subjects were asked to rate the 
tolerability of the IP based on the following criteria at the end of the treatment: 
Table 5. Assessment of tolerability 
Good  No side effects 
Fair  Mild to moderate side effects 
Poor  Severe side effects requiring withdrawal of subject 
 
 
4.6  DATA QUALITY ASSURANCE 
 
Before study initiation, it was ensured that the protocol -stipulated study procedures 
were well-understood by the investigator and his study staff .The study was monitored 
regularly for compliance to ICH-GCP, protocol and regulatory requirements. At each 
monitoring visit, CRF entries were verified by comparing them with the source CSR, VigRX Plus  Version 1.2  08/05/2010 
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documents before retrieving the case report forms. The monitor was to ensure that the 
investigator maintained accurate, timely, and complete records.  
 
4.7  STATISTICAL METHODS 
4.7.1  SAMPLE SIZE ESTIMATION 
For this exploratory pilot study, it was estimated that a sample size of 60 subjects would 
be sufficient to detect a difference in IIEF scores between VigRX Plus and placebo 
group at a significance level of 5%.  
4.7.2  ANALYSIS POPULATIONS 
Two types of populations were identified for analysis  
Intention –To -Treat Population (ITT) population were subjects who were recruited into 
the  study  and  who  received  at  least  one  dose  (or  any  portion  of  a  dose)  of  study 
medication. Analysis of safety variables were done for the ITT population. 
Per-Protocol  (PP)  population  consisted  of  completed  subjects  i.e.  all  subjects  who 
completed the study according to the following definition: 
Definition for a completed case:  Subject was considered a completed case if he fulfilled 
at least 84 days of treatment. (w.r.t. IIEF & EDITS patient version) 
Note:  
•  For this study even those subjects whose female partners  did not participate, 
were considered as completed subjects & their data were to be analyzed.  
•  EDITS  partner  version  assessment  was  to  be  done  for  only  those  female 
partners who gave informed consent and for whom data was available.  
Drop out, withdrawal and protocol deviation cases were to be reported and described.  
Missing, unused and spurious data were to be identified and appropriately taken care of 
during the final  analysis.  Missing  data  was  to  be  inserted  using  the  last  observation 
carried forward (LOCF) method.  CSR, VigRX Plus  Version 1.2  08/05/2010 
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4.7.3  HYPOTHESES 
The null hypothesis (H0) was that no difference exists in both primary and secondary end 
points between both the groups and the alternative hypothesis (HA) was that there exists 
a difference between the groups 
Primary hypothesis:  
1.  The score of IIEF-A will increase from baseline to Day 84. 
2.  This increase will be more in the active group as compared to placebo group. 
Secondary hypotheses:  
The secondary hypotheses to be investigated were 
•  Levels of secondary response variables improve from Day 1 up to day 84 (to be 
tested per variable).  
•  The  safety  variables  (CBC,  ESR,  Liver  Profile,  Renal  Profile,  &  ECG)  may  not 
change from screening to day 84  
 
4.7.4  METHODS OF ANALYSIS 
 
•  The final analysis was performed at the end of the study (Day 84) after database 
lock. 
•  Basic statistic evaluations include mean, standard deviation, median, min-max, 
etc… 
•  All efficacy and safety variables  were exploratively analyzed and descriptively 
evaluated. Thereby the structure equality of the 2 arms was especially verified. 
Thus, initially univariate and co-variate analysis of all the variables (qualitative, 
quantitative and ordinal) was carried out to determine the basic features of data 
like range, central tendency, spread etc. Then all the variables were compared 
across the groups to see the broad differences between them.  
•  Descriptive statistics (mean, standard deviation and N for continuous and count 
variables; median, range and N for discrete variables) of the primary response 
variable (IIEF - A) and each of the secondary response variables was done using 
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•  The  primary  endpoint  the  Erectile  Function  subscale  of  International  Index  of 
Erectile Function Questionnaire (IIEF-A) was compared between the treatment 
and placebo groups at baseline & end of treatment. Secondary Efficacy variables 
(IIEF-total,  IIEF-B,  EDITS  Patient  &  Partner  version,  Semen  Analysis,  S. 
Testosterone) were also compared between the treatment and placebo groups at 
baseline  &  end  of  treatment.  These  were  the  quantitative  variables  and  were 
mainly assessed by quantitative statistics. Adequate statistical tests such as the t 
test (paired for before and after data, unpaired if between the two groups), chi-
square test, U-test, ANOVA, ANCOVA etc, were applied. Friedman/ Wilcoxon 
(for  before  and  after  data)  Mann-Whitney  (between  the  two  groups) 
nonparametric test were used to confirm these results.  
•  Nominal  variables  in  the  study  such  as  global  assessment  of  therapy  were 
assessed by the chi-square test. 
•  All statistical tests were performed at 5% significance level (p < 0.05). 
•  For  demographic  and  other  remaining  variables  (vital  parameters,  clinical 
examination, and lab tests which include Complete Blood Count (CBC), ESR, 
SGPT, Creatinine and Routine Urine) are concerned, initially univariate analysis 
was  carried  out.  They  were  then  compared  across  the  groups  by  adequate 
statistical tests such as the t test, chi-square test, U-test, etc.  
•  Adverse/Serious Adverse Events were analysed using appropriate statistical test. 
•  The following statistical softwares were used: - SPSS 15, PEPI, EPI INFO 2000 
and MS Excel XP. 
 
Interim Analysis and Data Monitoring 
No interim analysis was planned for the trial. CSR, VigRX Plus  Version 1.2  08/05/2010 
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5  STUDY PATIENTS 
5.1  DISPOSITION OF PATIENTS 
Out of 108 patients screened, 78 were recruited into the study. Failure to meet the 
stipulated IIEF scores and laboratory abnormalities were the major reasons for 
screening failures (Table 6). The eligible subjects were randomized to receive either 
VigRX Plus or placebo. While one subject from the placebo group (VL/DM/63) was 
withdrawn due to his unwillingness to continue participation in the study after Day 56, 
two others(VL/DM/37and VL/DM/20 were lost to follow up after Day 28 and Day 56. 
 Fig 2.displays the disposition of subjects in the study.  
 
Table 6. Reasons for screening failure 
Site ID  IIEF  Laboratory abnormalities  Other 
VL/DM/01  4  3  0 
VL/DM/02  0  6  2 
VL/DM/03  1  0  1 
VL/DM/04  0  2  1 
VL/DM/05  3  3  2 
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Screening failures= 28
IIEF (N=8)
Lab (N =14)
Others (N=6)
Received VigRx Plus Received Placebo
Total completed
(N= 75)
Day 84
(N= 39)
Day 84
(N= 36)
(N=39)
Day 56 Day 56
(N= 39) (N= 38)
N= 78
(N= 39) (N= 36)
Day 28 Day 28
Screened
N=108
Recruited
(N=39)
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5.2  PROTOCOL DEVIATIONS 
 
There were no major protocol violations which led to withdrawal of subjects from the 
study. A majority of the protocol deviations were related to due to delay in scheduled 
laboratory test or tests not conducted due to various reasons. Appendix 10.2.1 
summarizes the protocol deviations at each study site.  
6  EFFICACY EVALUATION 
6.1  DATA SETS ANALYSED 
Analysis of safety (vital parameters) was done on an ITT population consisting of data 
on 78 subjects in whom at least one post baseline measurement was available. Analysis 
of laboratory parameters however was done only on subjects in whom complete data 
was available for screening and end of treatment visit. 
Efficacy evaluation was performed on a per-protocol data set of completed cases, in 
which data on all the protocol stipulated visits was available for IIEF and EDITS 
questionnaires. Analysis of all other efficacy parameters were done for subjects in whom 
complete data is available for the respective parameter 
 
6.2  DEMOGRAPHIC CHARACTERISTICS 
The two study groups appeared to be well balanced in terms of mean age of their 
subjects. (Table 7) 
 Table 7. Demographic characteristics 
Demographic characteristics   VigRx Plus 
(N=39) 
Placebo 
(N=39) 
Age (yrs.)  35.23 ± 13.24  34.33 ± 11.78 
Values are expressed as mean ± 2SD 
 
6.3    PRE-EXISTING CONDITION/CONCOMITANT MEDICATIONS USED IN 
STUDY 
A list of concomitant medications used in the study is provided in Appendix 10.3. All 
concomitant medications used were indicated for pre-existing conditions of the subjects 
or for treatment of adverse events. CSR, VigRX Plus  Version 1.2  08/05/2010 
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6.4  EFFICACY RESULTS 
6.4.1  PRIMARY EFFICACY MEASURES 
6.4.1.1  IIEF A 
Treatment with VigRX Plus showed a statistically significant (p=<0.0001) increase of 
IIEF A erectile function scores from baseline to endpoint at Day 84 as compared to 
placebo. 
 
In subjects receiving VigRX Plus the ability to penetrate the partner (Q3 of IIEF) and 
maintain erection after penetration (Q4 of IIEF) saw a greater improvement than in those 
receiving placebo (Table 8).  
Table 8. Responses to IIEF question 3 and 4   
  Baseline   Day 84   Improvement 
Ability to penetrate the partner (Q3 of IIEF) 
VigRX Plus 
(N=39) 
2.69 ± 1.12  4.12 ± 1.6  58.97 % 
Placebo 
(N=36) 
2.64 ± 1.08  2.63 ± 1.38  4.86 % 
Ability to maintain erection after penetration(Q4 of IIEF) 
VigRX Plus 
(N=39) 
2.56 ± 1.1  4.02 ±1.62  62.82 % 
Placebo 
(N=36) 
2.44 ± 1.1  2.66 ± 1.34  10.18 % 
IIEF scores are expressed as Mean ±2SD 
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Table 9. Effect on IIEF scores 
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Graph 1.Effect on IIEF A scores.*p=<0.0001 indicates significantly different from baseline, as 
compared to placebo by ANCOVA 
 
 
 
 
 
 
 
  Baseline  Day 28  Day 56  Day 84 
IIEF A 
VigRX  Plus 
(N=39) 
16.08 ± 5.82  20.03 ± 6  22.46 ± 7.14  25.08 ± 9.12 
Placebo 
 (N= 36) 
15.86 ±  6.48  16.33  ± 6.98  16.39 ± 7.42  16.47 ± 8.5 
IIEF TOTAL 
VigRX Plus 
(N=39) 
42.56 ± 10.18  52.15 ± 10.96  58.05 ± 14.54  63.13 ± 20.12 
Placebo (N= 36)  42.47 ± 10.20  43.86 ±  10.66  43.69 ± 6.95  43.86 ± 16.9 
IIEF B 
VigRX  Plus 
(N=39) 
26.49 ± 5.92  32.13 ± 6.34  35.59 ± 8.46  38.05 ± 11.38 
Placebo (N= 36)  26.61 ± 5.82  27.53 ± 6.36  27.31 ± 8.58  27.39 ± 9.84 
IIEF scores are expressed as mean ± 2SD CSR, VigRX Plus  Version 1.2  08/05/2010 
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6.4.2  SECONDARY EFFICACY PARAMETERS 
6.4.2.1  IIEF TOTAL SCORE 
Effect of VigRX Plus in increasing total IIEF scores from baseline to end of treatment (at 
Day 84) was statistically significant over that of placebo. (Graph 2.) 
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Graph 2.Effect on IIEF Total scores. *p<0.001indicates significantly different from baseline as 
compared to placebo, by ANCOVA. 
 
   
6.4.2.2  IIEF B 
On Day 84, subjects of the VigRX Plus group saw a statistically significant increase 
(p=<0.0001) of IIEF B scores from baseline as compared to placebo. Improvement in 
IIEF B scores is described in Table 9.  
Orgasmic function 
Subjects on VigRX Plus saw a greater improvement of orgasmic function than in those 
on placebo as assessed by the increase in question 10 and 11 of the international index. 
Sexual desire 
Enhancement of sexual desire was greater in subjects of the VigRX Plus group as 
compared to those of the placebo group.   
Overall satisfaction 
Scores of overall satisfaction were higher in the VigRX Plus than in the placebo group. CSR, VigRX Plus  Version 1.2  08/05/2010 
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Table 10. Effect on IIEF domains 
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Graph 3. Percentage improvement in IIEF domains 
IIEF 
DOMAINS 
  VigRX Plus 
(N=39) 
Placebo 
(N=36) 
    Baseline 
(Mean±2SD)  
Day 84 
(Mean±2SD) 
Improve
ment 
 
Baseline 
(Mean±2SD) 
Day 84 
(Mean±2SD) 
Improve
ment 
Erectile 
function 
Q1-6  16.08 ± 5.82  25.08 ± 9.12  60.35%  15.86 ±  6.48  16.47 ± 8.5  2.07 % 
Q7  1.92±1.06  3.17±1.37  1.94±2.42  2.38±1.29 
Q8  2.69±0.56  4.20±0.8  2.61±1.08  2.66±1.34 
Intercourse 
satisfaction 
Q9  2.66±0.52  4.20±0.80 
71.43% 
2.58±1.1  2.66±1.34 
14.03% 
Q 10  4.58±0.49  4.84±0.36  4.44±1.2  4.58±1.20  Orgasmic 
function  Q 11  3.25±0.63  4.38±0.93 
22.49% 
3.33±1.58  3.19±2.28 
-0.46% 
Q12  3.17±0.55  4.51±0.68  3.25±1.26  3.22±1.52  Sexual desire 
Q13  3.17±0.55  4.53±0.68 
47% 
3.22 ±1.26  3.19±1.48 
2.08% 
Q14  2.82±0.50  4.10±0.91  2.94±0.82  2.91±1.1  Overall 
satisfaction  Q15  2.64±0.70  4.07±0.87 
61% 
2.66±1.34  2.55±2.04 
-3.7% 
IIEF scores are expressed as Mean±2 SD CSR, VigRX Plus  Version 1.2  08/05/2010 
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6.4.2.3  EDITS 
Patient version 
In subjects receiving VigRX Plus, EDITS scores on Day 28, 56 and 84 were statistically 
significantly higher(p<0.0001) than that in those receiving placebo. 
The results of EDITS (patient and partner version) are summarized in Table 11 and 12. 
 
Table 11. Effect on EDITS (patient version) 
  Day 28  Day 56  Day 84 
VigRX Plus 
(N=39)  65.44 ± 36.28  76.10 ± 40.92  82.31 ± 40.46 
Placebo 
 (N= 36)  40.17 ± 32  36.61 ± 39.6  36.78 ± 45.06 
EDITS(patient version) scores are expressed as Mean ±2SD 
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Graph 4.Effect on EDITS (patient version) scores. *p<0.001indicates significantly higher than 
placebo, by independent sample t test CSR, VigRX Plus  Version 1.2  08/05/2010 
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Partner version 
Female partners of subjects receiving VigRX Plus reported statistically significantly 
higher (p<0.0001) scores than those of subjects receiving placebo. 
 
Table 12. Effect on EDITS (partner version)  
  Day 28  Day 84 
VigRX Plus 
(N=12)  69.58 ± 34.24  82.75 ± 19.6 
Placebo 
 (N= 10)  25.50 ± 20.24  18.50 ± 18.88 
EDITS(partner version)scores are expressed as Mean±2SD 
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Graph 5.Effect on EDITS scores (partner version). *p<0.001indicates significantly higher than 
placebo, by independent sample t test 
 
6.4.2.4  SEMEN ANALYSIS 
Sperm count 
The mean sperm count in the VigRX Plus group decreased from 49.45 million/ml at 
baseline to 47.15 million/ml on day 84 (Table 13). The change however was not 
statistically significant as compared to placebo. 
Semen volume 
The semen volume in both study groups increased from baseline to day 84. The 
increase in the VigRX Plus group was not statistically significant as compared to 
placebo. CSR, VigRX Plus  Version 1.2  08/05/2010 
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Sperm motility 
There was no statistically significant difference between the VigRX Plus and placebo 
groups with respect to changes in the sperm motility when compared from baseline to  
 end of treatment. (Table 14) 
 
Table 13.Effect on sperm count and semen volume 
  Sperm count (million per ml)  Semen volume (ml) 
  Baseline  Day 84  Baseline  Day 84 
VigRX Plus 
(N=22) 
49.45 ± 55.7  47.15 ± 50.62  1.75 ± 1.26  2.11 ± 1.06 
Placebo 
(N=18) 
58.29 ± 60.04  63.97 ± 41.66  1.97 ± 1.4  2.22 ± 1.76 
Values for sperm count are expressed as Mean±2SD 
 
Table 14. Effect on sperm motility 
 
  VigRX Plus   Placebo 
Grade of Sperm motility  Grade of sperm motility 
Visit 
Sperm  
Motility 
(%) 
IV 
 
III 
 
II 
 
I 
 
IV 
 
III 
 
II 
 
I 
 
After 1 hr   45±50.68  25±30.54  11±9.24  18±40.10  51±341  24±29.14  11±9.44  17±23.24 
After 2 hr   42±84.46  28±31.9  11±11.52  19±42.98  47±28.7  28±31.22  13±13.22  17±22.02 
After 3 hr   38±23.14  25±35.44  16±15.4  21±44.52  44±23.34  29±29.94  17±14.26  19±21.06 
S
c
r
e
e
n
i
n
g
 
After 6 hr   33±19.38  21±26.76  19±21.36  25±47.1  37±24.70  24±25.76  23±20.88  21±21.98 
After 1 hr   48±17.39  24±26.54  15±9.98  13±13.32  51±45.22  27±25.02  17±18.94  15±21.74 
After 2 hr   43±17.98  28±25.4  16±12.66  16±17.34  43±51.1  27±26.32  19±20.76  21±21.68 
After 3 hr   36±30.88  31±29.1  19±7.26  16±14.16  38±51.64  30±31.62  20±18.26  23±24.30 
D
a
y
8
4
 
After 6 hr   29±15.52  30±35.78  20±17.54  20±18.7  33±48.86  29±42.0  20±19.08  24.62 
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6.4.2.5  SERUM TESTOSTERONE 
The serum testosterone levels in subjects receiving VigRX Plus were not statistically 
significant with respect to change from screening to end of treatment as compared to 
placebo. (Table 15) 
Table 15. Effect on Serum testosterone 
  Serum testosterone (ng/dL) 
Screening 
Serum testosterone (ng/dL) 
Day 84 
VigRX Plus 
(N=37) 
544.46  ±  415.28  527.66  ± 310.94 
Placebo 
(N=25) 
518.1  ± 395.02  471.75  ± 320.76 
S. Testosterone values are expressed as Mean ± 2SD 
 
  
6.4.2.6  GLOBAL ASSESSMENT OF THERAPY BY INVESTIGATOR  
Global assessment of therapy by investigator on Day 84 saw a statistically significant 
superiority (p<0.0001) of VigRX Plus over placebo when analysed by Chi-square test.  
Table 16. Global assessment of therapy by Investigator  
Global assessment of therapy  VigRX Plus  Placebo 
Excellent  8 (20.15%)  -- 
Very Good  18 (46.15%  -- 
Good  11(28.21%)  2(5.56%) 
Fair  ----  8(22.22%) 
Poor  2(5.13%)  26(72.22%) 
 
 
6.4.2.7  SUBJECT’S OPINION 
At the end of treatment (Day 84), the proportion of subjects in the VigRX Plus group who   
wished to continue receiving the trial medication, was statistically significantly higher 
than those in the placebo group.  CSR, VigRX Plus  Version 1.2  08/05/2010 
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Graph 6.Subjects opinion. *p<0.0001indicates significantly different as compared to placebo, by 
Chi-square test 
  
7  SAFETY EVALUATION 
7.1  EXTENT OF EXPOSURE 
96.15% of the study population had a maximum exposure to VigRX Plus at a dose of 2 
capsules per day for 84 days. The least exposure to VigRX Plus was for 28 days and 
occurred in only one subject.  
7.2  ADVERSE EVENTS 
7.2.1  SUMMARY OF ADVERSE EVENTS 
Out of a total of 23 adverse events occurring in the study, 11 were reported from the 
VigRX Plus group and 12 from placebo group. The most common (7/23) adverse event 
was fever of mild severity, with the incidence of the event being similar in both study 
groups. A listing of adverse events by treatment group is displayed in Table 17. One 
serious adverse event occurred during the entire course of the study. Subject DM05 
receiving VigRX Plus suffered from infection due to malarial parasite (Plasmodium 
Vivax). The event was severe in intensity and led to hospitalization of the subject. Initially 
reported at the Day 84 visit, the event resolved after a period of eight days on 16.08 09. 
The investigator withdrew the subject from the study, but did not consider the event as 
related to the study medication. 
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Table17. Incidence of adverse events 
 Group  Subject 
ID 
Description of AE  Severity  Onset  Relation to 
IP 
VigRX Plus 
1  DM02  Pruritus  Mild  Day 28  Probable 
2  DM04  Acidity  Mild  Day 28  Probable 
3  DM05  Malaria  Severe  Day 84  Not related 
4  DM08  Chest Pain  Mild  Day 28  Probable 
5  DM11  Fever  Mild  Day 28  Not related 
6  DM11  Fever   Mild  Day 84  Not related 
7  DM19  Fever   Mild  Day 28  Not related 
8  DM19  Bodyache  Mild  Day 28  Not related 
9  DM62  Sticky discharge from urine  Mild  Day 84  Possible 
10  DM82  Sticky discharge from urine  Moderate  Day 84  Possible 
11  DM85  Fever   Mild  Day 1  Not related 
Placebo 
12  DM01  Cough and cold  Mild  Day 84  Not related 
13  DM03  Fever  Mild  Day 28  Not related 
14  DM06  Oedema of both lower 
extremities 
Mild   Day 28  Probable 
15  DM09  Cough   Mild  Day 28  Not related 
16  DM09  Fever   Mild  Day 28  Not related 
17  DM09  Fever   Mild  Day 56  Not related 
18  DM09  Cough  Mild  Day 56  Not related 
19  DM10  Acidity  Mild  Day 84  Not related 
20  DM10  Cough   Mild  Day 84  Not related 
21  DM17  Acidity  Moderate  Day 84  Probable 
22  DM17  Cold and cough  Mild  Day 84  Not related 
23  DM17  Oedema of fingers  Mild   Day 84  Not related CSR, VigRX Plus  Version 1.2  08/05/2010 
 
CONFIDENTIAL    Page 42 of 56   
 
7.3  CLINICAL LABORATORY EVALUATION 
7.3.1  VITAL PARAMETERS 
Table 18 displays the values for vital parameters assessed at baseline and end of 
treatment. In both study groups, there was a statistically significant increase of pulse rate 
as compared to baseline. The increases however were not clinically significant. No other 
significant changes of vital parameters were observed in any of the study groups.  
 
Table 18. Assessment of vital parameters 
Baseline Day84 Baseline Day84 Baseline Day84 Baseline Day84
VigRx Plus 
(N= 39)
74.82 ± 12.8 78.54* ± 12.04 17.97 ± 2.54 18.21 ± 1.96 120.56 ± 17.46 120.77 ±  13.64 78.62 ± 10.42 79.69 ± 9.64
Placebo 
(N=39) 75.72 ± 10.46 78.05* ± 9.92 18.41 ± 4.1 18.62 ± 3.3 122.21 ± 13.98 121.44 ± 12.98 79.95 ± 9.82 80.05 ± 9.2
Diastolic blood pressure 
(mmHg)
Pulse rate                         
(per min)
Respiration rate           (per 
min)
Systolic blood pressure           
(mm Hg)
 Values of vital parameters are expressed as Mean ± 2SD. * p< 0.05 is significant as compared to baseline 
by paired - t test.   
 
7.3.2  LABORATORY EVALUATION 
7.3.2.1  HAEMATOLOGICAL PARAMETERS 
Changes in the values of haematological parameters are displayed in Table 19. 
 
No significant changes were observed in any of the laboratory safety variables in 
subjects receiving VigRx Plus. In those receiving placebo, a statistically significant 
change occurred in the Day 84 values of a few laboratory parameters when compared to 
baseline. Mean eosinophils count increased whereas total RBC count, haemoglobin 
(Hb), and ESR decreased significantly (p<0.05) in the placebo group. These changes 
however were not of clinical importance. CSR, VigRX Plus  Version 1.2  08/05/2010 
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Table 19. Assessment of laboratory (blood) parameters 
 
  Hemoglobin (g/dl)  Total RBC (mill/mul)  Total WBC (thou/mul) 
  Baseline  Day 84  Baseline  Day 84  Baseline  Day 84 
VigRX 
Plus 
(N=36) 
14.92±2.52  14.94±2.32  5.10±0.86  5.07±0.76  7.50±3.7  7.14±3.66 
Placebo 
(N=25)  15.31±1.82  14.94±1.88*  5.09±0.92  4.86±1.12*  7.33±3.5  7.11±3.06 
  Neutrophils  Monocytes  Eosinophils 
  Baseline  Day 84  Baseline  Day 84  Baseline  Day 84 
VigRX 
Plus 
(N=36) 
60.33±20.1  58.36±16.94  5.72±4.1  6.11±4.68  4.53±10.24  4.11±6.94 
Placebo 
(N=25)  59.52±22.72  57.96±21.7  4.84±3.44  5.08±3.92  3.56±5.8  5.72±10.28 
             
  Basophils(%)  Lymphocytes(%)  ESR 
  Baseline  Day 84  Baseline  Day 84  Baseline  Day 84 
VigRX 
Plus 
(N=36) 
0.36±0.98  0.42±1.1  29±17.56  31±14.2  3.92±6.28  3.22±6.12 
Placebo 
(N=25)  0.32±0.96  0.20±0.41  30.32±16.46  31.04±14.92  3.32±2.92  2.80±5.8* 
             
  Serum creatinine(mg/dl)  Platelet count  SGPT 
  Baseline  Day 84  Baseline  Day 84  Baseline  Day 84 
VigRX 
Plus 
(N=36) 
0.89±0.26  0.90±0.38  255.64±140.76  274.06±121.0
6  24.72±22.24  26.42±26.72 
Placebo 
(N=25)  0.90±0.3  0.97±0.4  243.43±113.12  250.13±90.06  26.16±20.66  26.40±22.48 
Values of laboratory parameters are expressed as Mean ± 2SD. * p< 0.05 is significant as compared to 
baseline by Wilcoxon signed rank test.   CSR, VigRX Plus  Version 1.2  08/05/2010 
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7.3.2.2  URIINE ANALYSIS 
There was no incidence of any clinically significant findings in the urine routine tests of 
both study groups.  
7.3.3  ECG RESULTS 
No clinically significant abnormalities of ECG were reported in any of the study groups. 
7.4  TOLERABILITY 
There was no statistically significant difference found between the tolerability of 
treatment in the two study groups. 
Table 20. Assessment of tolerability 
Overall assessment of tolerability  VigRX Plus  Placebo 
Very good  31(79.49%)  28(77.78%) 
Good  8(20.51%)  5(13.89%) 
Fair  ---  3(8.33%) 
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8  DISCUSSION AND CONCLUSION 
The present study was designed to evaluate the efficacy and safety of VigRX plus 
capsules in erectile dysfunction and male sexual health. Erectile dysfunction is known to 
affect over half of all men between 50 and 70 years of age, and by the age of 40, about 
40% of men may suffer from some form of erectile dysfunction
12.  Although the advent of 
PDE5 inhibitors has revolutionized the medical management of sexual dysfunction, a 
major limitation to this therapy, along with safety concerns, is the inability to improve 
sexual desire in men. In this study an attempt was made to address this treatment gap 
by evaluating the effect of VigRX Plus in male subjects with sexual dysfunction. 
 
Assessment of efficacy was based on patient reported measures; clinician reported 
measures and laboratory evidence. In combination, these outcome measures aimed at 
evaluating the various aspects that determine the quality of sexual function in men. 
 
The erectile function domain of international index of erectile function (IIEF) was the 
primary efficacy parameter of this study. The instrument is widely accepted by regulatory 
agencies and scientific journals as a valid and reliable measure of sexual functioning in 
men. Treatment with VigRX Plus for 12 weeks led to enhanced quality of erectile 
function as evidenced by a statistically significant increase(p=<0.0001) of the IIEF A 
scores as compared to placebo. The ability to penetrate and maintain erections 
improved by 58% and 62.82% in the VigRX Plus group and 4.86% and 10.18% in the 
placebo group.  
 
Improvement in other domains of the international index as assessed by the increase in 
IIEF B scores, was also statistically significantly higher (p=<0.0001) with VigRX Plus 
than with placebo. Increases in IIEF scores for sexual desire and intercourse satisfaction 
were greater in subjects receiving VigRX Plus than in those receiving placebo. While 
orgasmic function and overall satisfaction enhanced by 22.49% and 61% respectively in 
VigRX Plus group, the parameters failed to find any improvement in the placebo group.  
 
Overall, the differences in outcomes between the two groups clearly established that 
VigRX Plus was superior to placebo in improving the erectile function of men. The CSR, VigRX Plus  Version 1.2  08/05/2010 
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findings are consistent with effectiveness of Korean red ginseng in treating ED in 
randomized controlled trials
13 
 
Here, it is noteworthy to mention that the improvement of IIEF scores achieved by VigRX 
Plus are at least comparable, if not equivalent to those reported by Sildenafil in an open 
label study of twelve weeks
14. A mean improvement of 60.35% in erectile function with 
VigRX Plus in this study is comparable with a 66% improvement noted with Sildenafil in 
the open label study. Further more, in subjects treated with VigRx Plus the increase in 
sexual desire (47%) was even higher than that reported with Sildenafil (13%) in the same 
study. Because Sildenafil and other PDE5 inhibitors do not produce
 but only facilitate 
erections
15, the effect of VigRX Plus in improving sexual desire is of considerable worth 
and may prove useful for initiation of sexual stimulation –a critical step in the sexual 
response cycle of men. 
 
Another important finding of this study was that treatment satisfaction of patients was 
corroborated by partner evaluations. Female partners of VigRX Plus treated men 
showed significantly higher levels (p<0.0001) of treatment satisfaction (EDITS -partner 
version) than those of placebo treated men. Since partner satisfaction is considered as 
one of the important determinants of sexual dysfunction, improved EDITS (patient and 
partner version) scores with VigRX Plus are predictive of a potential value of VigRX Plus 
as a long term ED therapy.   
 
The beneficial effect of VigRX Plus was further confirmed as a significantly larger 
proportion of men elected to continue receiving VigRX Plus after end of the study period. 
Global efficacy assessment by investigator was also in favour of VigRX Plus.  
 
VigRX Plus did not demonstrate any significant effect on the semen analysis 
parameters. A possible explanation could be the small number of observations obtained 
for this parameter due to socio-cultural influences. Considering the favourable effect of 
VigRX Plus on the spermatogonial cells (unpublished preclinical study) further 
investigation of VigRX Plus on semen parameters in an adequately sized sample is 
necessitated.    
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Sexual disorders in males, especially erectile dysfunction and decreased libido, have 
often been investigated for their relationship with testosterone- the male hormone. 
Despite the well-established role of testosterone in enhancing libido, its exact 
contribution to erections in men remains unclear
16.
 VigRX Plus in this study showed an 
improvement in erectile function scores and a concurrent increase in libido but without 
any significant change in the serum testosterone levels. It could be therefore inferred 
upon that effect of VigRX Plus is not due to any testosterone mediated mechanism. 
Besides, the evidence of a Rho-kinase inhibiting activity in an in vitro assay as 
mentioned earlier in this report, suggests a potential mechanism for this product and its 
evaluation in future studies. 
 
Safety of VigRX Plus as demonstrated in this study is desirable in the event of concerns 
with current pharmacological therapies. Although Sildenafil and other PDE5 inhibitors 
are effective and well tolerated in
 the treatment of most patients with ED, patients taking 
nitrate medications
 and /or certain alpha-blockers cannot take selected PDE5
 inhibitors.  
With no major adverse effects attributable to VigRX Plus in this study, and no significant 
difference occurring in the tolerability of treatment between the two groups, VigRXPlus in 
this study proved to be safe in subjects with sexual dysfunction.  
 
A limitation of this study is that it excluded patients with organic causes and risk factors 
of ED including vascular disease, diabetes mellitus, hypertension etc. Because most 
men with ED have an organic cause, the results of this study are not generalizable to a 
larger ED population. Thus evaluation of VigRx Plus in subjects with an underlying 
cause of ED is warranted in further studies. 
 
Conclusion 
In conclusion, use of VigRX Plus for twelve weeks was significantly better than placebo 
in improving erectile function in subjects with sexual dysfunction. It was also significantly 
superior to placebo in improving the other aspects of sexual health such as libido, 
intercourse satisfaction, orgasmic function and overall satisfaction. The enhancement of 
sexual function was endorsed by female partners of subjects receiving VigRX Plus. 
VigRX Plus was safe and well tolerated in subjects with male sexual dysfunction.  
      ____________________________ CSR, VigRX Plus  Version 1.2  08/05/2010 
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10 APPENDICES 
10.1 STUDY INFORMATION 
10.1.1  LIST OF CONCOMITANT MEDICATIONS PROHIBITED 
Medications know to cause Male Sexual Dysfunction such as: 
Antihypertensives & Diuretics:  
Hydrochlorothiazide,  Furosemide,  Bumetanide,  Methyldopa,  Clonidine,  Guanabenz, 
Guanfacine,Verapamil,  Nifedipine,  Hydralazine,  Enalapril,  Lisinopril,  Metoprolol, 
Propranolol, Atenolol, Losartan,Spironolactone etc 
Antidepressants, anti-anxiety drugs and antiepileptic drugs  
Fluoxetine,  Sertraline,  Amitriptyline,  Amoxipine,  Clomipramine,  Nortriptyline  
Phenelzine,  Chlordiazepoxide,  Clorazepate,  Diazepam,  Imipramine,  Lorazepam, 
Oxazepam, Phenytoin. 
Antihistamines 
Diphenhydramine, Hydroxyzine, Meclizine, Promethazine  
Non-steroidal anti-inflammatory drugs 
Naproxen, Indomethacin  
Parkinson's disease medications 
Biperiden, Benztropine, Trihexyphenidyl, Procyclidine, Bromocriptine, Levodopa  
Antiarrythmics :Digoxin 
Disopyramide (Norpace) 
Histamine H2-receptor antagonists 
Cimetidine, Nizatidine 
OHA- Pioglitazone 
Anti-androgens (ketoconazole, spironolactone) 
 
 
 
10.1.2  DEFINITION OF SERIOUS ADVERSE EVENT 
A serious adverse is defined as an adverse event which:  
- results in death 
- is life threatening 
- requires in patient hospitalization or prolongation of hospitalization 
- results in permanent or persistently significant disability 
- is a congenital anomaly or birth defect  
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10.1.3  IIEF QUESTIONNAIRE 
 
   Question  Response  Points 
Erectile function  
no sexual activity  0 
almost never or never  1 
a few times (much less than half the time)  2 
sometimes (about half the time)  3 
Most times (much more than half the time)  4 
1  How often were you able to get an 
erection during sexual activity? 
 
almost always or always  5 
no sexual activity  0 
almost never or never  1 
a few times (much less than half the time)  2 
sometimes (about half the time)  3 
Most times (much more than half the time)  4 
2  When you had erections with sexual 
stimulation, how often were your 
erections hard enough for 
penetration? 
  
almost always or always  5 
did not attempt intercourse  0 
almost never or never  1 
a few times (much less than half the time)  2 
sometimes (about half the time)  3 
Most times (much more than half the time)  4 
3  When you attempted sexual 
intercourse, how often were you able 
to penetrate (enter) your partner? 
  
almost always or always  5 
did not attempt intercourse  0 
almost never or never  1 
a few times (much less than half the time)  2 
sometimes (about half the time)  3 
Most times (much more than half the time)  4 
4  During sexual intercourse, how often 
were you able to maintain your 
erection after you had penetrated 
(entered) your partner? 
   
almost always or always  5 
did not attempt intercourse  0 
extremely difficult  1 
very difficult  2 
difficult  3 
slightly difficult  4 
5  During sexual intercourse, how 
difficult was it to maintain your 
erection to completion of 
intercourse? 
 
not difficult  5 
very low or none at all  1 
Low  2 
moderate  3 
High  4 
6  How do you rate your confidence 
that you could get and keep an 
erection? 
   very high  5 
Intercourse Satisfaction 
no attempts  0 
1-2 attempts  1 
3-4 attempts  2 
5-6 attempts  3 
7-10 attempts  4 
7  How many times have you attempted 
sexual intercourse? 
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did not attempt intercourse  0 
almost never or never  1 
a few times (much less than half the time)  2 
sometimes (about half the time)  3 
most times (much more than half the time)  4 
8  When you attempted sexual 
intercourse, how often was it 
satisfactory for you? 
   
almost always or always  5 
no intercourse  0 
no enjoyment  1 
not very enjoyable  2 
fairly enjoyable  3 
highly enjoyable  4 
9  How much have you enjoyed sexual 
intercourse? 
 
  
very highly enjoyable  5 
Orgasmic Function 
no sexual stimulation or intercourse  0 
almost never or never  1 
a few times (much less than half the time)  2 
sometimes (about half the time)  3 
most times (much more than half the time)  4 
10  When you had sexual simulation or 
intercourse, how often did you 
ejaculate? 
  
   almost always or always  5 
no sexual stimulation or intercourse  0 
almost never or never  1 
a few times (much less than half the time)  2 
sometimes (about half the time)  3 
most times (much more than half the time)  4 
11  When you had sexual stimulation or 
intercourse, how often did you have 
the feeling of orgasm or climax? 
   
almost always or always  5 
Sexual Desire 
almost never or never  1 
a few times (much less than half the time)  2 
sometimes (about half the time)  3 
most times (much more than half the time)  4 
12  How often have you felt sexual 
desire? 
  
   almost always or always  5 
   
   
very low or none at all  1 
low  2 
moderate  3 
high  4 
13  How would you rate your level of 
sexual desire? 
  
very high  5 
Overall Satisfaction 
very dissatisfied  1 
moderately dissatisfied  2 
About equally satisfied and dissatisfied  3 
moderately satisfied  4 
14  How satisfied have you been with 
your overall sex life? 
  
very satisfied  5 
very dissatisfied  1 
moderately dissatisfied  2 
About equally satisfied and dissatisfied  3 
moderately satisfied  4 
15  How satisfied have you been with 
your sexual relationship with your 
partner? 
   very satisfied  5 
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10.2 TABLES REFERRED TO BUT NOT INCLUDED IN THE TEXT 
10.2.1  PROTOCOL DEVIATIONS 
Subject No  Reason for deviation 
Dr. Gaurang Shah 
DM06& DM07  IP not returned on Day 28 visit 
DM10  IP not returned on Day 28 visit 
DM01,DM05,DM07,DM59,DM60 
and DM61 
Extended washout period  
DM01, DM04, DM07 and DM62  Delay in laboratory testing and Semen analysis  
DM08 
The subjects IP compliance calculation was 75 
% when calculated at Day 84  
DM09  IP not returned on Day 56 visit 
DM62   IP not returned on Day 28 visit  
DM03  ECG and Semen Analysis not performed 
DM05 
Delay in laboratory testing for Day 84 visit was 
by more than 15 days 
DM05  ECG and Semen analysis not performed  
DM06  Laboratory testing not performed for Day 84 visit 
DM07 
ECG report of Day 84 is lost from the site and 
thus no ECG reporting is mentioned in the CRF 
DM08  Semen Analysis not done for the subject 
DM10  IP compliance as 73.80% for Day 84 visit 
DM60  IP  compliance  as  75.64%  when  calculated  on 
Day 84 visit 
DM10, DM60 and DM61  Laboratory testing not performed for Day 84 visit 
DM59  ECG and Semen Analysis not performed 
Dr. Manoj Chaudhari 
DM31 
Subject enrolled in the study with out of normal 
range TSH levels. Accepted Lower limit – 0.245 
units. Subject value – 0.24 units.   
DM31 
Subject unable to give semen sample even after 
repeated attempts.  
DM32  Semen analysis not performed  
DM22, DM24, DM31, DM32,DM88 
and DM47, DM57, DM67 and 
DM68. 
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Dr. Patankar 
DM50 
IP not returned on day 28 visit. 
DM50  Delay in Laboratory evaluation 
DM50  IP not returned  
DM51  Delay in Laboratory evaluation 
Dr. Pensalwar 
DM19 
IP not returned on day 28 visit 
DM17, DM19, DM20, DM80, DM84  IP not returned on day 28 visit 
DM15  IP not returned on day 56 visit 
DM11 and DM12  Day 84 visit delayed by 12 days  
DM19, DM20, DM80 and DM84.  IP not returned on day 28 visit 
DM16  Subject reported 13 days early for  Day 28 visit  
Dr. Sable 
DM036,DM037  Extended wash out period 
DM042  Extended wash out period 
DM40,DM42  IP not returned on day 28 visit 
DM45  IP not returned on day 28 visit 
DM38. DM41, DM42, DM43, DM44.  Laboratory testing was not done within +3 or -3 
days of scheduled visit. 
DM45  Laboratory testing for Day 84 visit 
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10.2.2  LISTING OF PATIENTS RECEIVING INVESTIGATIONAL PRODUCT  
 
ID  Initials 
DM02  RDS 
DM04  TSP 
DM05  RSC 
DM08  ASS 
DM11  SMS 
DM12  PMV 
DM13  SAS 
DM14  MFS 
DM18  DNK 
DM19  VBK 
DM21  RCT 
DM23  SNR 
DM25  MMT 
DM28  AMP 
DM30  PKP 
DM31  RRW 
DM33  CKR 
DM39  ADB 
DM40  MUM 
DM41  NBG 
DM42  RBB 
DM46  NMM 
DM49  HPM 
DM54  NJP 
DM57  UAK 
DM59  IFG 
DM62  DBG 
DM64  DGP 
DM67  SSN 
DM68  SDL 
DM70  AKG 
DM71  YVZ 
DM74  PVM 
DM80  JBC 
DM81  SAW 
DM82  SRM 
DM85  MRJ 
DM88  SSK 
DM90  DEP 
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10.3 PRE-EXISTING CONDITION/CONCOMITANT MEDICATION USED IN 
THE STUDY 
 
ID  Initials 
Concomitant 
Medication (CM)  CM Dose 
CM Start 
Date 
CM End 
Date 
CM 
Indication 
DM03  PMS  Paracetamol  500 mg bd  7/2/2009  10-07-2009  Fever 
DM06  TCV  Diclofenac gel  Twice a day  12/26/2008  Ongoing  Backache 
Pentamazole  150 mg OD  10/4/2009  10-10-2009  Acidity  DM10  BKG 
Tab Cetrizine  50 mg O.D.  10/9/2009  Ongoing  Cough 
Tab-Paracetamol  500 mg B.D.  7/16/2009  17-07-2009  Fever  DM11  SMS 
Tab-Diclofenac  100 mg  9/30/2009  01-10-2009  Fever 
DM17  JBC  Pentaprazole  100 mg BD  10/13/2009  22-10-2009  Acidity 
Paracetamol  500 mg BD  8/18/2009  21-08-2009  Fever  DM19  VBK 
Diclofenac   50 mg B.D.  8/18/2009  21-08-2009  Body pain 
DM84  SRK  Pentaprazole  100 mg OD  11/1/2009  Ongoing  Acidity 
DM85  MRJ  Paracetamol  500 mg  8/10/2009  13-08-2009  Fever 
Note: The term ‘ongoing’ in the above table refers to pre-existing conditions  
 
 
 
 
 
 
 